Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

Table 2 Patient-level characteristics and outcomes of the 12 patients who underwent apheresis but were not infused

ID	Age band (year)	EMD	PCL	High-risk cyto	R-ISS	Prior lines	Intended product	Bridging regimen (category)	Days apheresis → attrition event	Reason not infused	Subsequent therapy	Outcome (months from apheresis)
N-01	60-64	Yes	No	No	II	7	Ide-cel	None	176	Infection (bacteraemia, prolonged admission)	None	Died, 5.8
N-02	80-84	No	No	No	II	4	Ide-cel	None	11	Non-myeloma death (COVID-19, pulmonary embolism)	None	Died, 1.0
N-03	75-79	Yes	No	No	I	6	Ide-cel	Antibody-drug conjugate	70	Non-myeloma death (ischaemic stroke)	None	Died, 2.3
N-04	60-64	Yes	Yes	Yes	II	4	Cilta-cel	PI + BCL2 inhibitor + steroid	34	Manufacturing failure (out-of-specification product)	BCMA bispecific	Died, 6.2
N-05	55-59	Yes	No	No	II	5	Cilta-cel	None	24	Progressive disease + intracranial haemorrhage	None	Died, 0.8
N-06	75-79	Yes	No	Yes	II	4	Ide-cel	Radiotherapy	71	Progressive disease → bowel ischaemia	None	Died, 2.3
N-07	40-44	No	Yes	Yes	III	5	Cilta-cel	None	51	Progressive disease; declined further therapy	None	Lost to follow-up; censored 1.7
N-08	80-84	Yes	No	No	II	5	Cilta-cel	Alkylator + PI + steroid	47	Progressive disease	None	Died, 1.5
N-09	65-69	Yes	No	Yes	II	5	Ide-cel	BCMA bispecific	33	Progressive disease	None	Died, 1.1
N-10	60-64	Yes	Yes	No	III	8	Cilta-cel	None	5	Progressive disease	None	Died, 0.2
N-11	80-84	Yes	No	Unknown	Unknown	7	Ide-cel	None	196	Collection failure (inadequate CD3+ yield)	GPRC5D bispecific	Alive, 11.7
N-12	70-74	No	No	No	II	5	Cilta-cel	None	42	Progressive disease	None	Died, 1.4

Median time from apheresis to the attrition event: 44 days (interquartile range: 30-72; range 5-196). Eight of 12 events (66.7%) occurred within 60 days. Ages are banded and no dates are reported, to protect confidentiality. BCMA: B-cell maturation antigen; EMD: Extramedullary disease; GPRC5D: G protein-coupled receptor class C group 5 member D; PCL: Plasma cell leukaemia; PI: Proteasome inhibitor; R-ISS: Revised International Staging System; COVID-19: Coronavirus disease 2019; BCL2: B-cell lymphoma 2.